Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer

Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer

Conditions: Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Stage IV Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride; Drug: Selinexor; Other: Pharmacological Study; Other: Laboratory Biomarker Analysis; Drug: Nab paclitaxel
Sponsors: Mohammed Najeeb Al Hallak
Completed

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 8, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments